Cytokinetics Inc

CYTK remains under distribution pressure, with price rejecting at the 9- and 20-period EMAs and approaching its rising 200-day SMA. The active Post-Parabola Collapse pattern identifies mean-reversion eligibility, shifting the medium-term bias to bullish despite the short-term downtrend. However, tactical execution remains unfavorable until price can reclaim and accept above the short-term EMAs. Therefore, entries should be deferred ("Stalk") around the 200-day SMA support, awaiting a clear reversal signal.

• ↑Q2 revenue of $28.6M outperforms $17.1M forecast; MYQORZO nets $25.3M with 40% share
• ↑Cash and investments of ~$1.7B fund commercialization through early 2026
• ↓Q2 R&D spending rose to $112.6M, straining cash runway